VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
NCT06828055 on ClinicalTrials.gov · last registry update 2025-10-06
An unusually large phase 2: 280 participants, more than double the 114 typical for the stage. The sponsor logged completion for 24 June 2025. Primary outcome, as filed: Percent (relative) change from baseline in body weight after 13 weeks of treatment. VK2735 is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Drug
- VK2735
- Sponsor
- Viking Therapeutics, Inc.
- Sponsor type
- Industry
- Enrollment
- 280
- Started
- 2024-12-18
- Primary completion
- 2025-06-24 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent (relative) change from baseline in body weight after 13 weeks of treatment
Conditions studied
Weight Loss
Every field above is taken directly from the registry record. See all detected changes across the class, or the VK2735 page for this molecule’s full trial and approval history.